JEAN-PIERRE BIZZARI
CIK 1630914 · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$171.2K
Companies
5
Total Filings
28
Lifetime Open-Market Net
-$1.46M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| APRE | Director | 4,180 | $0.61 | $2.6K | $0 | 3 | 2026-06-17 |
| ADCT | Director | 151,902 | $1.11 | $168.6K | -$20.2K | 5 | 2026-06-03 |
| HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Director | 66,815 | — | — | -$1.44M | 11 | 2023-05-09 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Director | — | $13.60 | — | $0 | 5 | 2020-01-28 |
| Celator Pharmaceuticals Inc (CPXX) Delisted | Director | — | — | — | $0 | 3 | 2016-07-12 |
Recent Filings · Page 2 of 3
28 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-05-06 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | +6,206 | $0 | EDGAR |
| 2021-08-25 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Sell (S) | −35,000 | -$1.44M | EDGAR |
| 2021-05-06 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | +5,230 | $0 | EDGAR |
| 2020-05-01 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | +8,829 | $0 | EDGAR |
| 2020-01-28 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-03 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | +12,173 | $0 | EDGAR |
| 2019-01-29 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-02 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | +10,363 | $0 | EDGAR |
| 2018-01-29 | PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-05 | HALOZYME THERAPEUTICS, INC. (HTI) Delisted | Grant (A) | +14,135 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.